Biogen CEO Michel Vounatsos will be stepping down from his position after more than five years at the helm, with this development coming not long after Medicare decided to limit coverage of his company’s Alzheimer’s drug Aduhelm. In an earnings report, Biogen said a new CEO has yet to be appointed. Vounatsos will stay on … Continue reading Biogen CEO stepping down after Medicare decision on Alzheimer’s drug